Objective-Macrophage foam cell formation is a key feature of atherosclerosis. Recent studies have shown that specific microRNAs (miRs) are regulated in modified low-density lipoprotein-treated macrophages, which can affect the cellular cholesterol homeostasis. Undertaking a genome-wide screen of miRs regulated in primary macrophages by modified low-density lipoprotein, miR-302a emerged as a potential candidate that may play a key role in macrophage cholesterol homeostasis. Approach and Results-The objective of this study was to assess the involvement of miR-302a in macrophage lipid homeostasis and if it can influence circulating lipid levels and atherosclerotic development when it is inhibited in a murine atherosclerosis model. We found that transfection of primary macrophages with either miR-302a or anti-miR-302a regulated the expression of ATP-binding cassette (ABC) transporter ABCA1 mRNA and protein. Luciferase reporter assays showed that miR-302a repressed the 3′ untranslated regions (UTR) activity of mouse Abca1 by 48% and human ABCA1 by 45%. In addition, transfection of murine macrophages with miR-302a attenuated cholesterol efflux to apolipoprotein A-1 (apoA-1) by 38%. Long-term in vivo administration of anti-miR-302a to mice with low-density lipoprotein receptor deficiency (Ldlr −/− ) fed an atherogenic diet led to an increase in ABCA1 in the liver and aorta as well as an increase in circulating plasma high-density lipoprotein levels by 35% compared with that of control mice.
A therosclerosis is a chronic inflammatory disease of the arterial wall, as well as a disorder of lipid metabolism. 1 Cholesterol is an essential structural component in the cell membrane and a precursor in metabolic pathways, including steroid hormone and bile acid synthesis. The accumulation of cholesterol-loaded macrophages in the arterial wall, termed foam cell formation, is a hallmark feature of early atherosclerotic lesions. 2 Low-density lipoprotein (LDL) particles are internalized by macrophages in the arterial wall via multiple pathways including through the LDL receptor (LDLR) on the cell surface and hydrolyzed to free cholesterol in lysosomes. 3 When excessive cholesterol is taken up in the artery wall, macrophages activate a compensatory pathway to efflux the cholesterol, mediated by the ATP-binding cassette (ABC) transporters, such as ABCA1 and ABCG1. 4 These transporters promote cellular cholesterol efflux to high-density lipoprotein (HDL) and its associated apolipoprotein A-1 (apoA-1), a crucial step in the initiation of reverse cholesterol transport to the liver for excretion. 5 During systemic hypercholesterolemia, however, this homeostatic mechanism is overwhelmed, leading to the development of foam cells and fatty streak lesions. 6 Lipid loaded and activated macrophage foam cells can significantly contribute to the maintenance and progression of atherogenesis by producing nitric oxide, reactive oxygen species, inflammatory lipids, growth factors, and proinflammatory cytokines (eg, interleukin-1, interleukin-6, interferon-γ, and tumor necrosis factor-α). 7 Understanding the mechanisms that regulate these responses could, therefore, be of considerable value in developing new approaches to the prevention and treatment of atherosclerosis. The regulation of these lipid February 2015 metabolism mediators such as ABCA1, however, is complex and likely to involve post-transcriptional mechanisms.
MicroRNAs (miRs) are a recently recognized class of highly conserved, noncoding short RNA molecules that regulate gene expression at the post-transcriptional level. MiRs act as negative regulators of gene expression by inhibiting messenger RNA (mRNA) translation or promoting mRNA degradation. 8 Importantly, several miRs have been recognized recently to influence cholesterol homeostasis. [9] [10] [11] [12] Because complex metabolic pathways, such as lipid metabolism, are often coordinately regulated by a variety of homeostatic mechanisms and 1 gene can be under the repressive mechanism of multiple miRs, we performed an unbiased genome-wide screening of miRs regulated in mouse bone marrow-derived macrophages (BMDM) with or without treatment with modified LDL. We identified miR-302a as a potential candidate targeting ABCA1 leading us to hypothesize that miR-302a is involved in cholesterol transport and efflux.
On the basis of our findings that miR-302a regulates ABCA1 at the post-transcriptional level and anti-miR-302a treatment prevents atherosclerosis progression, miR-302a may be a promising therapeutic target to treat atherosclerosis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Regulation of miR-302a Is Inversely Correlated With Cellular Cholesterol Levels
It has been shown that specific miRs can be regulated as well as regulate many different functions in macrophages, including cholesterol homeostasis. Therefore, we performed an unbiased genome-wide screen of miRs modulated by cellular cholesterol content in primary macrophages. We identified a subset of 47 miRs differentially regulated in mouse macrophages by cholesterol enrichment ( Table I in the online-only  Data Supplement) , of which 14 were downregulated and 33 were upregulated. Confirmation of these miR candidates using real-time polymerase chain reaction identified miR-302a as one of the most strongly modulated miRs in BMDM after treatment with modified LDL. MiR-302a expression in BMDM was significantly downregulated by acetylated LDL (AcLDL) and oxidized LDL stimulation for 6 hours in vitro. This was accompanied by the upregulated expression of the cholesterol transporter genes Abca1 and Abcg1 ( Figure 1A) . Interestingly, stimulation with native LDL does not seem to affect miR-302a expression but does upregulate ABC transporter genes. To show that these observations are valid in the human system as well, we performed the same experiment using freshly isolated human peripheral blood mononuclear cells. Real-time polymerase chain reaction analysis using primary human macrophages confirmed the results seen in BMDM. MiR-302a was significantly downregulated after treatment with AcLDL or oxidized LDL for 6 hours with a concomitant upregulation of ABCA1 and ABCG1 gene expression ( Figure 1B ). Next, we investigated miR-302a expression in the aorta of Ldlr −/− mice that had been fed a normal chow or a high-fat diet for 8, 12, and 24 weeks. We found that miR-302a was highly expressed in the aorta of these mice. However, consistent with our in vitro findings, after 12 weeks of atherogenic diet feeding, miR-302a was markedly downregulated, whereas Abca1 and Abcg1 gene expression was upregulated ( Figure 1C ). This pattern suggests that miR-302a is regulated by hypercholesterolemia in Ldlr −/− mice. 
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Molecular Characteristics of miR-302a
Analysis of sequence alignment revealed that miR-302a is an intrinsic miR localized on chromosome 4 in humans and on chromosome 3 in mice, both within intron 8 of the La ribonucleoprotein domain family member 7 (LARP7) gene ( Figure 2A ). LARP7 belongs to the LARP RNA-binding protein family, and modulates the metabolism and function of a variety of RNA species. 13 Many mammalian miRs are located within introns of protein-coding genes and, therefore, are typically coordinately expressed and processed with the precursor mRNA in which they reside. 14, 15 Accordingly, the mature form of miR-302a seems to be coexpressed with the Larp7 host gene in several different mouse tissues examined ( Figure 2B ). Interestingly, miR-302a is highly expressed in the aorta in comparison with Larp7, whereas in the spleen Larp7 is abundantly expressed with little expression of miR-302a. In addition, we found that in liver, aorta, and BMDM, miR-302a and Larp7 expression were coordinately downregulated by cholesterol loading suggesting the regulation of miR-302a by cholesterol ( Figure 2C ). Moreover, miR-302a is highly conserved in different organisms ( Figure 2D ), which led us to investigate miR-302a for further validation of its role in cholesterol metabolism. MiRs have been shown to target mRNAs for post-transcriptional repression by base-pairing with mRNA sequences typically located in the 3′UTRs and causing translational inhibition or mRNA cleavage. 16 To gain insight into the function of miR-302a, we analyzed its potential gene targets using 4 different prediction programs, such as miRanda, miRwalk, Pictar, and TargetScan, which predict binding sites on mRNAs for a particular candidate miR (Table II in the online-only Data Supplement). We identified a potential binding site for miR-302a in the 3′UTR of the human and mouse ABCA1 gene ( Figure 2E and 2F, respectively), a strong indication that miR-302a indeed plays a role in cholesterol metabolism via ABCA1 regulation.
MiR-302a Regulates ABCA1 in Primary Macrophages at the Post-Transcriptional Level
To test the specific effect of miR-302a on ABCA1 expression, we treated BMDM with AcLDL (to load the cells with cholesterol) or the liver X receptor ligand T0901317 (to directly stimulate the expression of ABCA1) after transfecting the cells with mimic miR-302a to increase the intracellular levels of miR-302a. Our data show that mimic miR-302a strongly decreased the stimulation of Abca1 mRNA and protein ( Figure 3A and 3C; Figure IA in the online-only Data Supplement) in primary mouse macrophages. MiR-302a upregulation, however, had no effect on the related Abcg1 gene expression. To further determine whether miR-302a is specifically involved in regulating Abca1 expression in BMDM, we inhibited endogenous miR-302a by transfecting the BMDM with an anti-miR-302a construct. Introduction of anti-miR-302a indeed resulted in increased levels of Abca1 mRNA and protein ( Figure 3B and 3D; Figure IB in the online-only Data Supplement). As with mimic miR-302a, no effect on Abcg1 expression was observed. MiR-302a overexpression or knockdown were confirmed by real-time polymerase chain reaction analysis (data not shown). In summary, these data clearly indicate that Abca1 expression in primary mouse macrophages is regulated by miR-302a. Of note, BMDM transfected with anti-miR-302a showed a downregulation of inflammatory genes ( Figure 3E ) indicating a link between Abca1 expression and inflammation.
MiR-302a Specifically Targets the 3′UTR of Mouse and Human ABCA1 and Regulates Cellular Cholesterol Efflux to apoA-1
To determine the effects of miR-302a on the 3′UTR of human and mouse ABCA1, we used luciferase reporter constructs. As shown in Figure 4A -4C, cotransfection with mimic miR-302a markedly repressed both mouse and human ABCA1 3′UTR activity compared with control miR, suggesting that miR-302a is able to bind to the 3′UTR of both mouse and human ABCA1. Mutations in the seed base-pairing sequence of the predicted miR-302a target sites in the ABCA1 reporter abrogated the miR-302a repression of mouse and human 3′UTR activity, indicating a direct interaction of miR-302a with these sites (Figure 4B and 4C) . Together, these experiments identify ABCA1 as conserved target of miR-302a.
The ability of ABCA1 to stimulate the efflux of cholesterol from cells in the periphery, particularly cholesterol-laden macrophages in atherosclerotic plaques, is an important antiatherosclerotic mechanism. 5 Transfection of BMDM with miR-302a diminished cholesterol efflux to apoA-1 compared with control miR after treatment with AcLDL for 24 hours ( Figure 4D ). Similar results were seen using primary human macrophages ( Figure 4F ). Conversely, inhibition of endogenous miR-302a with antimiR-302a increased ABCA1 protein and cholesterol efflux to apoA-1 in primary murine and human macrophages ( Figure 4E and 4G) . Thus, manipulation of cellular miR-302a levels alters macrophage cholesterol-efflux capacity, a critical step in the reverse cholesterol transport pathway for the delivery of excess cholesterol to the liver. 5
Anti-miR-302a Treatment In Vivo Increases ABCA1 in Aorta and Liver of Ldlr −/− Mice
In addition to coordinating cellular cholesterol efflux, ABCA1 is also intimately involved in initiating HDL formation in the liver. 17 Therefore, we tested the effect of manipulating miR-302a levels in vivo in Ldlr −/− mice using 2′ fluoro/ methoxyethyl-modified phosphorothioate backbone antisense oligonucleotides provided by our collaborators at Regulus Therapeutics. The delivery of antisense nucleotides has been used successfully in mice to inhibit the function of various miRs and to increase expression of their target genes with no evident toxicity. 18 To assess the effects of inhibiting miR-302a in a model of atherosclerosis, Ldlr −/− mice were fed a high-fat diet >12 weeks while being injected intraperitoneally with anti-miR-302a or control anti-miR oligonucleotides.
Consistent with previous studies, 19 ,20 the treatment did not induce a detectable immune response, because differential blood count in mice treated with either control anti-miR or anti-miR-302a did not differ from those of untreated Ldlr −/− mice fed a high-fat diet. Efficient delivery was confirmed by measuring levels of its target gene ABCA1 in the livers and aorta of mice during euthanization. An increase was seen in 
Anti-miR-302a Treatment Increases Circulating HDL Levels and Reduces Atherosclerosis Progression in Ldlr −/− Mice
To determine if increased ABCA1 expression in the liver augments HDL biogenesis in anti-miR-302a-treated Ldlr −/− mice, we measured circulating plasma HDL as well as other lipid levels in anti-miR-302a and control anti-miR-treated mice.
There was a significant increase in total circulating cholesterol in mice treated with anti-miR-302a (Table) . Moreover, analysis of lipoproteins by high-performance liquid chromatography showed an increase in cholesterol content of the HDL fractions (45-58 minutes) of the anti-miR-302a-treated mice compared with that of control anti-miR-treated mice ( Figure 6A ). In fact, treatment of Ldlr −/− mice with anti-miR-302a raised HDL by 35% compared with that of control mice. Very low-density lipoprotein (VLDL)/LDL cholesterol was also raised in the anti-miR-302a-treated mice, but this was not statistically significant (Table) .
In assessing atherosclerotic lesion development, a marked reduction in plaque formation in aorta ( Figure 6B ) and in aortic roots ( Figure 6C ) was observed in Ldlr −/− mice treated with anti-miR-302a in comparison with Ldlr −/− mice treated with control miR, as visible after Oil red O staining. Interestingly, quantitative immunostaining revealed that the reduction of plaque area was associated with a significant increase in the relative content of macrophages ( Figure 6D ), whereas the necrotic core size was significantly decreased in anti-miR-302a Ldlr −/− mice ( Figure 6F ). In addition, the relative content of smooth muscle cells was significantly increased in anti-miR-302a-treated Ldlr −/− mice ( Figure 6E ) indicating remodelling of plaques toward a rather early and more stable lesion phenotype with a lesser degree of inflammation ( Figure 3E ). Together, these results indicate that anti-miR-302a treatment supports the efflux of cholesterol from plaque macrophages leading to an overall reduction in atherosclerotic burden.
Discussion
There is a strong evidence that high levels of circulating HDL are associated with positive cardiovascular outcomes, independent of levels of LDL cholesterol, and as such, therapies to raise HDL are actively being pursued. 21 Direct infusion of HDL in apoE-deficient mice 22 or human subjects 23 with established atherosclerosis, reduces plaque size. The ABC transporter ABCA1 is primarily responsible for initiating HDL formation in the liver. 24 This work reveals that miR-302a exerts post-transcriptional control of the ABCA1 cholesterol transporter in primary macrophages resulting in the regulation of cellular cholesterol efflux. By targeting Abca1 via in vivo delivery of anti-miR-302a in Ldlr −/− mice, circulating plasma HDL levels were increased leading to less atherosclerosis when compared with Ldlr −/− mice treated with a control anti-miR. However, further validation needs to be performed to identify the HDL type generated by anti-miR-302a treatment.
Although we demonstrated that miR-302a modulates Abca1 in primary macrophages, hepatocytes represent the primary metabolic cell type within the liver. Hoekstra et al 25 profiled murine hepatocyte miR expression during the development of nonalcoholic fatty liver and showed a decrease in miR-302a levels in response to western-type diet feeding, which coincided with a marked increase in the expression of the miR-302a target gene, Abca1. These findings support our results showing miR-302a is regulating Abca1 on a post-transcriptional level resulting in increased HDL levels in anti-miR-302a-treated Ldlr −/− mice. However, albeit not statistically significant, we also observed an ≈25% increase in VLDL/ LDL levels in those same mice. Although the reason for this increase is under active investigation, it is noteworthy that despite the raised VLDL/LDL levels there was a significant reduction in atherosclerosis in anti-miR-302a-treated mice. This is a strong indication that the antiatherogenic property exerted by a 35% increase in HDL far outweighed the proatherogenic property exhibited by a 25% rise in VLDL/LDL. There have been several reports of miRs regulating lipid metabolism. MiR-122, for example, was identified as the most highly expressed miR in the adult liver, where it accounts for 70% of all miRs. 26 Using antisense strategies, several groups have reported that inhibition of miR-122 in the liver results in sustained decreases in plasma cholesterol levels in both mice and nonhuman primates. 27, 28 Most recently, 5 independent studies demonstrated that miR-33a targets ABCA1 and ABCG1 and limits the efflux of cholesterol to apoA-1 in both macrophages and hepatocytes. [29] [30] [31] [32] [33] Conversely, antimiR-33a treatment upregulates ABCA1 expression both in vitro and in vivo, promoting the efflux of cholesterol to apoA-1 and increasing circulating HDL levels. 29, 32, 33 In addition to these findings, inhibition of miR-33 expression in vivo increases reverse cholesterol transport and curbs atherosclerotic plaque regression. 20, 34 Here, we report that a newly identified miR, miR-302a, targets ABCA1 and modulates the cholesterol efflux to apoA-1 in primary macrophages. In addition, anti-miR-302a treatment increases circulating HDL levels and decreases atherosclerosis development. Aside from ABCA1, VLDLr, Osbpl5, Pmvk, and lep are also predicted to be target of miR-302a, all of which can influence lipid metabolism ( Table II in the online-only Data Supplement). An interesting connection between lipid metabolism and inflammation in macrophages revealed by others suggests that cholesterol loading of macrophages results in a proinflammatory phenotype, whereas cholesterol efflux dampens this inflammation. [35] [36] [37] In our study, real-time polymerase chain reaction analysis of anti-miR-302a-transfected macrophages showed that aside from the regulation of Abca1 there was an alteration of the inflammatory state of these cells when compared with miR-302a-transfected cells. This likely led to less inflammation in the lesions of anti-miR-302a-treated Ldlr −/− mice, and, therefore, a slower progression of atherosclerosis.
As the host gene of miR-302a, LARP7 gene encodes a protein that is found in the 7SK small nuclear ribonucleoprotein. Although little is known about the function of this protein what is known is that this small nuclear ribonucleoprotein complex inhibits a cyclin-dependent kinase, which is required for paused RNA polymerase II at a promoter to begin transcription elongation. Via its ability to control transcription and elongation, LARP7 is thought to be involved in general cellular processes, such as cell growth and tumorigenesis. This makes it likely to be involved in a broad range of different processes, including inflammation and lipid metabolism, even though LARP7 is not a transcription factor regulating gene expression involved in cholesterol metabolism. Interestingly, a recent study showed that loss of function mutation in LARP7 causes a syndrome of facial dysmorphism, intellectual disability, and primordial dwarfism. 38 The ability of miRs to modulate important biological pathways offers opportunities for the manipulation of miR function using oligonucleotide inhibitors or miR mimics. Antisense oligonucleotides directed against specific miR sequences are efficiently taken up by a variety of tissues. 39 In addition, miR mimics and inhibitors are relatively stable in plasma and can simply be injected to reach their cellular gene targets without apparent toxicity. The challenge to directly target a specific inflamed tissue or a specific cell type is still remaining. However, Rayner et al 20 were able to show that anti-miR treatment indeed is capable of targeting plaque macrophages and directly altering gene expression in these cells supporting our data showing less plaque formation possibly because of a higher cholesterol-efflux rate in mice treated with anti-miR-302a.
Taken together, our data identify for the first time miR-302a as a modulator of cholesterol efflux and clearly highlights miR-302a to be an attractive therapeutic target for the prevention/treatment of atherosclerosis.
